Search clinical trials for: HSP90 Heat-Shock Proteins

Total 2131 results

Protgen Ltd

Unknown

Clinical Trial of Quantitative Detection Kit for Hsp90α in Breast Cancer

Breast Cancer

China
Novartis Pharmaceuticals

Completed

A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.

Non-small-cell Lung Cancer

Canada, France, Spain, Netherlands, Singapore, Germany, Korea, Republic of, Turkey, United States, Norway
Protgen Ltd

Unknown

Clinical Trial of Quantitative Detection Kit for Hsp90α in Colorectal Cancer

Colorectal Cancer

China
Myrexis Inc.

Completed

Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments

Cancer

United States
Novartis Pharmaceuticals

Completed

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Breast Cancer | Hematologic Neoplasms

Netherlands, Switzerland, United Kingdom, United States
Novartis Pharmaceuticals

Terminated

Dose Escalation of HSP990 in Japan/Korea

Advanced Solid Tumors

Japan
Novartis Pharmaceuticals

Terminated

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

Advanced Non Small Cell Lung Cancer (NSCLC)

France, Italy, Taiwan, Spain, Netherlands, Japan, Hong Kong, Korea, Republic of, Norway, United States, United Kingdom, Poland
Esanex Inc.
National Cancer Institute (NCI)

Completed

Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

Lymphoma | Leukemia | Solid Tumor Malignancy | Lymphoid Malignancy (Lymphoma and CLL)

United States
Herbert Lyerly

Terminated

A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies

Solid Tumor

United States
Novartis Pharmaceuticals

Completed

Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan

Advanced Solid Tumors

Japan
Astex Pharmaceuticals, Inc.

Completed

Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors

Metastatic Solid Tumors

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham... and other collaborators

Completed

STA-9090(Ganetespib) in Metastatic Ocular Melanoma

Ocular Melanoma

United States
Debiopharm International SA
Syneos Health

Terminated

A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC] (HALO)

Non-small Cell Lung Cancer

Spain, France, United Kingdom
Protgen Ltd

Unknown

Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer

Liver Cancer

China
Infinity Pharmaceuticals, Inc.

Terminated

Dose Escalation of IPI-493 in Hematologic Malignancies

Hematologic Malignancies

United States
Esanex Inc.

Completed

Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors

Cancer

United States
Esanex Inc.

Completed

Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies

Cancer

United States
Dale Shepard, MD, PhD
National Cancer Institute (NCI)

Terminated

Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Terminated

Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas

Neoplasms

United States
Memorial Sloan Kettering Cancer Center
Novartis

Terminated

HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET

Myeloproliferative Neoplasms

United States
Esanex Inc.

Completed

Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies

Cancer
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States, Philippines, United Kingdom
M.D. Anderson Cancer Center
Novartis

Terminated

A Study of the HSP90 Inhibitor AUY922

Lymphoma

United States
Synta Pharmaceuticals Corp.

Completed

An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer (Enchant)

Breast Cancer | Triple Negative Breast Cancer | HER-2 Positive Breast Cancer | ER/Progressive Response (PR) + Refractory to Prior Hormonal Treatment

Spain, United States, Argentina, Belgium, Brazil, Korea, Republic of, Peru, United Kingdom
David M. Jackman, MD
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Synta Pharmaceuticals...

Completed

Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

United States
Herbert Lyerly

Withdrawn

HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies

Solid Tumor

United States
Esanex Inc.
Pfizer; Serenex, Inc.

Completed

Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies

Cancer

United States
Biogen

Terminated

Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL

B-Cell Chronic Lymphocytic Leukemia

United States
Esanex Inc.
Serenex, Inc.

Completed

Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

Hematologic Neoplasms

United States
ARCIM Institute Academic Research in Complementary...

Recruiting

Efficacy of External Application of Rosemary Oil in Patients With Chemotherapy-Induced Peripheral Neuropathy: a Feasibility Study

Chemotherapy-induced Peripheral Neuropathy (CIPN)

Germany
Novartis Pharmaceuticals

Terminated

Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients

Advanced Gastric Cancer

Spain, Belgium, France, Italy, United States, Korea, Republic of, Japan, Germany
Biogen

Completed

Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors

Lymphoma | Tumors

United Kingdom, United States
Esanex Inc.

Completed

Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors

Cancer

United States
Esanex Inc.

Completed

Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma

Cancer

United States
Royal Marsden NHS Foundation Trust
Institute of Cancer Research, United Kingdom

Unknown

Analysis of Pharmacodynamic Changes With AUY922A, an HSP90 Inhibitor

Advanced Solid Malignancies

United Kingdom
Biogen

Terminated

Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL

Chronic Lymphocytic Leukemia

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Infinity Pharmaceuticals, Inc.

Terminated

IPI-504 in NSCLC Patients With ALK Translocations

Lung Cancer | Stage IV Lung Cancer | Stage IIIb Lung Cancer

United States
Esanex Inc.

Terminated

Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL

Cancer

United States
Esanex Inc.

Withdrawn

Safety and Activity of SNX-5422 Plus Ibrutinib in CLL

Cancer

United States
SCRI Development Innovations, LLC
Novartis Pharmaceuticals

Completed

A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors

Metastatic or Unresectable Solid Tumor Malignancy

United States
Emory University
Synta Pharmaceuticals Corp.

Terminated

Ganetespib Window of Opportunity Study in Head and Neck Cancers

Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage I Hypopharyngeal Squamous Cell Carcinoma | Stage I Laryngeal Squamous Cell Carcinoma | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II... and other conditions

United States
University Medical Center Groningen

Completed

89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition (AUY922)

Breast Cancer

Netherlands
Novartis Pharmaceuticals

Completed

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

Relapsed or Refractory Multiple Myeloma

Germany, Spain, Singapore, United States, Australia
Nanfang Hospital of Southern Medical University

Completed

The Role of HSP90 in Peripheral Vascular Lesions of Diabetic Atherosclerosis (rhsppvlda)

Peripheral Arterial Disease

China
University Medical Center Groningen

Completed

Imaging HSP90 Inhibitor AUY922 on VEGF-89ZR-bevacizumab Positron Emission Tomography (PET)

Breast Cancer

Netherlands
Meir Medical Center

Unknown

Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer

The Combined Effect of Hsp90 Inhibitor and HDAC/Proteasome Inhibitors on Lung Cancer Cell Fate and ER-Golgi Homeostasis Will be Examined.

Israel
Astex Pharmaceuticals, Inc.

Completed

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Prostate Cancer

United States, United Kingdom, Spain, Canada
Debiopharm International SA

Completed

Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma

Neoplasms | Lymphoma | Cancer | Solid Tumors

France
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.; Exelixis

Active, not recruiting

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Melanoma | Skin Cancer

United States
Novartis Pharmaceuticals

Completed

A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors

Advanced Solid Malignancies

France, Spain, Canada

Search clinical trials for: HSP90 Heat-Shock Proteins

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations